NEW YORK – Fabric Genomics said Wednesday that it has inked a partnership with Intermountain Children's Health to analyze whole-genome sequencing data provided by the Broad Clinical Labs to help diagnose infants and children suspected of genetic diseases.
Financial details of the deal were not disclosed.
According to Fabric, the collaboration aims to help speed the diagnosis of pediatric patients in inpatient and outpatient care settings, particularly for infants undergoing surgical repair of congenital heart disease, starting at Intermountain Primary Children's Hospital in Salt Lake City.
Using Fabric's AI-driven GEM platform, which can help prioritize and rank the variants based on their match to the patient's phenotype, Broad Clinical Labs, a wholly owned subsidiary of the Broad Institute, has been offering a sample-to-report clinical WGS service priced at $1,000 per sample.
"We are excited to integrate the Broad Clinical Labs' whole-genome sequencing service and Fabric's Enterprise software platform into the clinical workflow within our pediatric cardiac intensive care unit (CICU)," Martin Tristani-Firouzi, a pediatric cardiologist for the University of Utah Health and Intermountain Primary Children's Hospital, said in a statement. "This partnership allows us to quickly and cost-effectively access top-tier clinical-grade genome sequencing and reporting, more accurate diagnoses for these infants, and the ability to reanalyze the data, all of which ultimately will improve outcomes and enhance the quality of care we deliver to children."